Rivaroxiban versus Warfarin in management of deep venous thrombosis (DVT)

Abstract

Background: Venous thromboembolism (VTE), a disorder associated with a significant risk of morbidity and mortality, is composed of deep vein thrombosis (DVT) and pulmonary embolism (PE). Objectives: The aim of this study was to compare between rivaroxiban and warfarin regarding efficacy, safety and complications of treatment in patients with DVT. Patients and methods: This is a randomized controlled clinical trial. From April 2021 to April 2022, seventy patients with DVT were diagnosed and followed up in Vascular Surgery Department in Qena University Hospital regarding clinical presentation and venous duplex ultrasonography scans. Studied patients were divided into two groups, Group A treated by rivaroxiban and Group B treated by warfarin. Comparison between variables of two groups was performed regarding efficacy, safety and complications of treatment. Results: No significant differences between two groups were noticed regarding efficacy and clinical improvement while there was significant difference regarding bleeding as a complication e.g. bleeding in warfarin group as P value <0.05. Conclusion: Rivaroxiban and Warfarin seem to have same efficacy regarding symptoms relief and prevention of DVT recurrence. Rivaroxiban is better than warfarin regadring bleeding risk, safety in all age groups, compliance and follow up as no need of laboratory monitoring.

Keywords

• deep vein thrombosis (dvt); rivaroxiban; warfarin